GSK has signed up Exscientia of Dundee to provide AI technology to develop new drugs. If targets are met, Exscientia will receive $43 million from the deal, ‘We are the first company to automate drug design,’ says Exscientia. Exscientia claims to be able to identify new opportunities for new drugs in around a quarter of ...

This story continues at Glaxo turns to AI specialist Exscientia for new drug development

Or just read more coverage at Electronics Weekly